ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
China NMPA Accepts IND Application for Eftansomatropin Pivotal Trial in Pediatric Patients with Growth Hormone Deficiency
August 04, 2020I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the China National Medical Products Administration (NMPA) has accepted
Pharma Sources Insight January 2025
